Visiongate

The Cell-CT platform analyzes cells in true 3D and measures more than 900 morphology biomarkers per cell at 200 nm isometric resolution. LuCED AI identifies cells with abnormal features for cytological diagnosis.

Arizona State University’s Biodesign Institute will acquire the first commercially available Cell-CT imaging platform from VisionGate, Inc.

Dr. Alan Nelson, CEO of VisionGate, was named a Research Fellow at the International Prevention Research Institute (iPRI).

Swedish Cancer Institute collaborated with VisionGate to provide samples from lung cancer patients for development of a sputum test for early detection of lung cancer.

VisionGate, Inc. announced a collaboration with Seattle Cancer Care Alliance to clinically develop a lung cancer risk assessment test for current and former smokers. The test uses VisionGate’s Cell-CT platform to generate high-resolution 3D images.

VisionGate’s team includes scientists, researchers, and doctors with more than 150 years of combined experience. The team has experience developing technologies in pharmaceuticals and diagnostics, including early-stage lung cancer detection methods.

VisionGate’s mission is to save lives through the early detection and prevention of cancer. Its technologies are designed to detect early-stage lung cancer using a simple, non-intrusive test.

FPO

VisionGate, Inc. lists its address as 22121 17th Ave. SESTE E-114Bothell, WA 98021.

VisionGate is a biotechnology company that offers a quick, non-intrusive lung cancer test based on 3D cellular imaging and AI.

The page presents VisionGate website terms and conditions revised May 14, 2011, which govern website access and use.